MedTrace Logo

Effect of Sepsis Adsorption Column on Syndecan-1 and Mortality

NCT07033910 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 91

Last updated 2025-06-24

No results posted yet for this study

Summary

This observational, cross-sectional, single-center study aims to investigate the effect of extracorporeal sepsis adsorption column therapy on plasma Syndecan-1 levels and clinical outcomes in patients with sepsis. The study was conducted in the Internal Medicine Intensive Care Unit of Gülhane Training and Research Hospital. Patients were divided into two groups: one group received standard sepsis treatment along with an extracorporeal adsorption column (Biosky® MG350), while the other group received only standard treatment. Clinical and laboratory parameters, including Syndecan-1 levels, were evaluated to assess the potential impact of the adsorption column on sepsis-related outcomes.

Conditions

  • Sepsis
  • Syndecan 1
  • Extracorporeal Sepsis Adsorption Column

Interventions

DEVICE

sepsis adsorption column

after the initiation of fluid and antibiotic therapy according to the Surviving Sepsis Campaign 2021 Guidelines, an additional routine sepsis adsorption column (Biosky® MG350) was used within 48-72 hours.

Sponsors & Collaborators

  • Oral MENTEŞ

    lead OTHER

Principal Investigators

  • HUSEYIN L YAMANEL, MD, PhD · GULHANE SM

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-25
Primary Completion
2024-06-09
Completion
2024-06-09
FDA Device
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07033910 on ClinicalTrials.gov